Prostate palpation device for prostate cancer screening bancodepatentes - Banco de Patentes
Banco de patentes
Comité Tech Transfer. Webinar: TESTIMONIALS “De la investigación al emprendimiento”
Destinado: Comunidad investigadora. El contexto actual derivado de la situación pandémica obliga, más si cabe, a aunar esfuerzos para avanzar en la sociedad y la economía del conocimiento. El...
Premiadas dos tecnologías del Banco de Patentes, se presentarán en Bio Boston
Dos tecnologías del Banco de Patentes, Sistema de Sellado Epidural y Antisense RNA-therapeutics in Myotonic Dystrophy, entre las ganadoras del Programa de Aceleración Comercial Internacional FIPSE...
Back Prostate palpation device for prostate cancer screening bancodepatentes
Prostate palpation device for prostate cancer screening bancodepatentes
Currently, prostate cancer is screened with prostate specific antigen (PSA) blood testing and digital rectal examination, which detects cancer in 18% of patients with normal PSA. This physical examination has a disadvantage of subjectivity, as it depends on the experience of the examiner and the apprehension of the patient.
PROSTACTO is a device for prostate palpation as a screening method for prostate cancer, composed of a palpation system that transforms the collected information into objective, reproducible and useful, allowing the generation of an objective map of stiffness, reaching the entire peripheral area, in a short space of time and performed less aggressively than touch.
National Patent P202130115, dated February 15, 2021, jointly owned by the Valencia Institute of Biomechanics, the Polytechnic University of Valencia and the Higher Center for Scientific Research (CSIC).
